Effect of benzalkonium chloride on transscleral drug delivery

Investigative Ophthalmology and Visual Science

Volumn 46, Issue 2, 2005, Pages 703-708

  Okabe, Komei ^a   Kimura, Hideya ^b   Okabe, Junko ^a   Kato, Aki ^a   Shimizu, Hideo ^c   Ueda, Takashi ^a   Shimada, Shouichi ^a   Ogura, Yuichiro ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b Nagata Eye Clinic   (Japan)

^c NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BENZALKONIUM CHLORIDE; BETAMETHASONE SODIUM PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS HUMOR; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG PENETRATION; DRUG SAFETY; ELECTROPHYSIOLOGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; RABBIT; SPECTROFLUOROMETRY;

ANIMALS; AQUEOUS HUMOR; BENZALKONIUM COMPOUNDS; BETAMETHASONE; CHOROID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEXTRANS; DRUG DELIVERY SYSTEMS; EYE; FLUORESCEIN-5-ISOTHIOCYANATE; GLUCOCORTICOIDS; INFUSION PUMPS, IMPLANTABLE; PERMEABILITY; PRESERVATIVES, PHARMACEUTICAL; RABBITS; RETINA; SAFETY; SCLERA; SPECTROMETRY, FLUORESCENCE; VITREOUS BODY;

EID: 13944251659     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.03-0934     Document Type: Article

References (32)

1. Jaffe GJ, Pearson PA, Ashton P. Dexamethasone sustained drug delivery implant for the treatment of severe uveitis. Retina. 2000; 20:402-403.
2. Jaffe GJ, Ben-nun J, Guo H, Dunn JP, Ashton P. Fluocinolone acetonide sustained drug delivery to severe uveitis. Ophthalmology. 2000;107:2024-2033.
3. Sanborn GE, Anand R, Torti RE, et al. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Arch Ophthalmol. 1992;110:188-195.
4. Herrero-Vanrell R, Refejo MF. Biodegradable microspheres for vitreoretinal drug delivery. Adv Drug Deliver Rev. 2001;52:5-16.
5. Ambati J, Canakis CS, Miller JW, et al. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci. 2000;41:1181-1185.
6. Ambati J, Gragoudas ES, Miller JW, et al. Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci. 2000;41:1186-1191.
7. Geroski DH, Edelhauser HF. Transscleral drug delivery for posterior segment disease. Adv Drug Deliver Rev. 2001;52:37-48.
8. Okabe J, Kimura H, Kunou N, et al. Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate. Invest Ophthalmol Vis Sci. 2003;44:740-744.
9. Cunha-Vaz JG. The blood-ocular barriers, review. Surv Ophthalmol. 1979;23:279-296.
10. Cunha-Vaz JG. The blood-ocular barriers: past, present, and future. Doc Ophthalmol. 1997;93:149-157.
11. Lopez A, Llinares F, Cortell C, et al. Comparative enhancer effects of Span20 with Tween20 and Azone on the in vitro percutaneous penetration of compounds with different lipophilicities. Int J Pharm. 2000;202:133-140.
12. Cruysberg LP, Nuijts RM, Geroski DH, et al. In vitro human scleral permeability of fluorescein, dexamethasone-fluorescein, methotrexate-fluorescein and rhodamine 6G and the use of a coated coil as a new drug delivery system. J Ocul Pharmacol Ther. 2002;18: 559-569.
13. Morimoto K, Uehara Y, Iwanaga K, et al. Influence of absorption enhancers (bile salts) and the preservative (benzalkonium chloride) on mucociliary function and permeation barrier function in rabbit tracheas. Eur J Pharm Sci. 1998;6:225-230.
14. Quan YS, Fujita T, Kamiyama F, et al. Electrophysiological studies on the evaluation of absorption enhancers in Caco-2 cells using a microelectrode technique. Biol Pharm Bull. 2000;23:738-742.
15. Aihara M, Lindsey JD, Weinreb RN. Enhanced FGF-2 movement through human sclera after exposure to latanoprost. Invest Ophthalmol Vis Sci. 2001;42:2554-2559.
16. Kim JW, Lindsey JD, Wang N, et al. Increased human scleral permeability with prostaglandin exposure. Invest Ophthalmol Vis Sci. 2001;42:1514-1521.
17. Weinreb RN. Enhancement of scleral macromolecular permeability with prostaglandins. Trans Am Ophthalmol Soc. 2001;99:319-343.
18. Russell SR, Shepherd JD, Hageman GS. Distribution of glycoconjugates in the human retinal internal limiting membrane. Invest Ophthalmol Vis Sci. 1991;32:1986-1995.
19. Heegaard S, Jensen OA, Prause JU. Structure and composition of tKe inner limiting membrane of the retina: SEM on frozen resin-cracked and enzyme-digested retinas of Macaca mulatta. Graefes Arch Clin Exp Ophthalmol. 1986;224:355-360.
20. Xu KP, Li XF, Yu FS. Corneal organ culture model for assessing epithelial responses to surfactants. Toxicol Sci. 2000;58:306-314.
21. Maurer JK, Parker RD, Carr GJ. Ocular irritation: microscopic changes occurring over time in the rat with surfactants of known irritancy. Toxicol Pathol. 1998;26:217-225.
22. Maurer JK, Parker RD, Petroll WM, et al. Quantitative measurement of acute corneal injury in rabbits with surfactants of different type and irritancy. Toxicol Appl Pharmacol. 1999;158:61-70.
23. Quan YS, Hattori K, Lundborg E, et al. Effectiveness and toxicity screening of various absorption enhancers using Caco-2 cell monolayers. Biol Pharm Bull. 1998;21:615-620.
24. Chou A, Hori S, Takase M. Ocular toxicity of beta-blockers and benzalkonium chloride in pigmented rabbits: electrophysiological and morphological studies. Jpn J Ophthalmol. 1985;29:13-23.
25. Miyake K, Ota I, Ibaraki N, et al. Enhanced disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema by topical timolol and its preservative in early postoperative pseudophakia. Arch Ophthalmol. 2001;119:387-394.
26. Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci. 2004;45:1360-1368.
27. Sasaki H, Nagano T, Yamamura K, et al. Ophthalmic preservatives as absorption promoters for ocular drug delivery. J Pharm Pharmacol. 1995;47:703-707.
28. Sasaki H, Igarashi Y, Nagano T, et al. Different effects of absorption promoters on corneal and conjunctival penetration of ophthalmic beta-blockers. Pharm Res. 1995;12:1146-1150.
29. Sasaki H, Ichikawa M, Kawakami S, et al. In-situ ocular absorption of ophthalmic beta-blockers through ocular membranes in albino rabbits. J Pharm Pharmacol. 1997;49:140-144.
30. Sasaki H, Yamamura K, Mukai T, et al. Modification of ocular permeability of peptide drugs by absorption promotors. Biol Pharm Bull. 2000;23:1524-1527.
31. Kato A, Kimura H, Okabe K, et al. Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant. Invest Ophthalmol Vis Sci. 2004;45:238-244.
32. Okabe K, Kimura H, Okabe J, et al. Intraocular tissue distribution of betamethasone after intrascleral administration using a non-biodegradable sustained drug delivery device. Invest Ophthalmol Vis Sci. 2003;44:2702-2707.